BeOne Medicines (MEX:BGNEN) E10: MXN-100.58 (As of Mar. 2026)


MEX:BGNEN BeOne Medicines Ltd MEX:BGNEN
81 GF Score
Price MXN2,858.16
GF Value MXN3,774.03
! 4 Warning Signs
View Full Analysis

What is BeOne Medicines E10?

BeOne Medicines MEX:BGNEN 81 E10 is MXN-100.58 as of Mar. 2026. GuruFocus rates MEX:BGNEN with a GF Score™ of 81/100 and a GF Value™ of MXN3,774.03. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

BeOne Medicines's adjusted earnings per share data for the three months ended in Mar. 2026 was MXN35.164. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is MXN-100.58 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-25), BeOne Medicines's current stock price is MXN2858.16. BeOne Medicines's E10 for the quarter that ended in Mar. 2026 was MXN-100.58. BeOne Medicines's Shiller PE Ratio of today is .


BeOne Medicines  (MEX:BGNEN) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


BeOne Medicines E10 Related Terms


BeOne Medicines E10 Historical Data

* Premium members only.

The historical data trend for BeOne Medicines's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeOne Medicines E10 Chart

BeOne Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -168.05 -101.13

BeOne Medicines Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -131.41 -91.86 -101.13 -100.58

MEX:BGNEN vs RVMD, RPRX, BNTX: E10 Comparison

For the Biotechnology subindustry, BeOne Medicines's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BeOne Medicines Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeOne Medicines's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where BeOne Medicines's Shiller PE Ratio falls into.


MEX:BGNEN
81GF Score
BeOne Medicines Ltd MEX:BGNEN
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BeOne Medicines E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BeOne Medicines's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=35.164/107.1957*107.1957
=35.164

Current CPI (Mar. 2026) = 107.1957.

BeOne Medicines Quarterly Data

per share eps CPI Adj_EPS
201606 -14.425 100.088 -15.449
201609 -20.109 99.604 -21.642
201612 -19.535 99.380 -21.071
201703 -24.478 100.040 -26.229
201706 -28.199 100.285 -30.142
201709 47.185 100.254 50.452
201712 -42.830 100.213 -45.814
201803 -37.789 100.836 -40.173
201806 -56.198 101.435 -59.390
201809 -46.201 101.246 -48.916
201812 -89.339 100.906 -94.908
201903 -55.478 101.571 -58.550
201906 -27.469 102.044 -28.856
201909 -100.092 101.396 -105.817
201912 -120.138 101.063 -127.428
202003 -110.285 101.048 -116.995
202006 -99.022 100.743 -105.364
202009 -106.284 100.585 -113.270
202012 -103.438 100.241 -110.615
202103 13.287 100.800 14.130
202106 -104.099 101.352 -110.101
202109 -97.109 101.533 -102.525
202112 -125.341 101.776 -132.016
202203 -85.418 103.205 -88.721
202206 -109.844 104.783 -112.373
202209 -107.213 104.835 -109.627
202212 -83.638 104.666 -85.659
202303 -60.924 106.245 -61.469
202306 -62.404 106.576 -62.767
202309 33.967 106.570 34.167
202312 -59.580 106.461 -59.991
202403 -40.993 107.355 -40.932
202406 -21.435 107.991 -21.277
202409 -23.038 107.468 -22.980
202412 -29.824 107.128 -29.843
202503 0.000 107.722 0.000
202506 14.687 108.075 14.567
202509 19.078 107.709 18.987
202512 9.363 107.196 9.363
202603 35.164 107.196 35.164

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of MXN-100.58 mean?
BeOne Medicines (MEX:BGNEN) has a E10 of MXN-100.58 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on BeOne Medicines and its competitors.
Is BeOne Medicines' E10 too high?
BeOne Medicines' current E10 is MXN-100.58. Overall, BeOne Medicines has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' E10 compare to RVMD and RPRX?
BeOne Medicines' E10 of MXN-100.58 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on BeOne Medicines and its competitors. BeOne Medicines's current E10 is MXN-100.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
BeOne Medicines (MEX:BGNEN) has a current E10 of MXN-100.58. The stock's GF Value™ is MXN3,774.03, compared to a current price of MXN2,858.16 — trading 24.3% below its estimated fair value. The current E10 is MXN-100.58. BeOne Medicines' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For BeOne Medicines (MEX:BGNEN), the current E10 is MXN-100.58 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BeOne Medicines (MEX:BGNEN) Overvalued in 2026?

Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued. The current stock price of MXN2,858.16 is trading 24.3% below its estimated GF Value™ of MXN3,774.03.

Key valuation signals for MEX:BGNEN:

  • E10: MXN-100.58
  • GF Value™: MXN3,774.03 vs. price of MXN2,858.16 (24.3% below fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the MEX:BGNEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BeOne Medicines Business Description

Address c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
81GF Score

Get the complete analysis for MEX:BGNEN

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,858.16
Price
MXN3,774.03
GF Value